# Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer

> **NCT01583322** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 188 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** vargatef
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01583322
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-05
- **Final completion:** 2016-03
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01583322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01583322, "Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01583322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*